Daniel N. Cortright

Repligen (United States) — United States

Neuroscience · Life Sciences

25h-index4.1kcitations37works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ion Channels and Receptors(19), Pain Mechanisms and Treatments(16), Stress Responses and Cortisol(8), Neuropeptides and Animal Physiology(7), Neurobiology and Insect Physiology Research(6)

Publications37 total

Pyrido[2,3-b]pyrazines, discovery of TRPV1 antagonists with reduced potential for the formation of reactive metabolites
Bioorganic & Medicinal Chemistry Letters·2010· 17 citedOpen Access
Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists
Journal of Medicinal Chemistry·2010· 37 citedOpen Access
Locomotor Activity in a Novel Environment as a Test of Inflammatory Pain in Rats
Methods in molecular biology·2010· 19 cited
TRP Channels and Pain
Current Pharmaceutical Design·2009· 143 cited
C5a, But Not C3a, Increases VEGF Secretion in ARPE-19 Human Retinal Pigment Epithelial Cells
Current Eye Research·2009· 51 cited
Transient Receptor Potential Channels on Sensory Nerves
Handbook of experimental pharmacology·2009· 65 cited
The Role of the Vanilloid and Related Receptors in Nociceptor Function and Neuroimmune Regulation
Neuroimmune biology·2008· 8 cited
Characterization of N-(Adamantan-1-ylmethyl)-5-[(3 R-aminopyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 Antagonist in Animal Models of Pain and Inflammation
Journal of Pharmacology and Experimental Therapeutics·2008· 77 cited
Identification and Characterization of NDT 9513727 [N,N-bis(1,3-Benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1 H-imidazole-5-methanamine], a Novel, Orally Bioavailable C5a Receptor Inverse Agonist
Journal of Pharmacology and Experimental Therapeutics·2008· 30 cited
New frontiers in assessing pain and analgesia in laboratory animals
Expert Opinion on Drug Discovery·2008· 25 cited
1-Benzylbenzimidazoles: The discovery of a novel series of bradykinin B1 receptor antagonists
Bioorganic & Medicinal Chemistry Letters·2008· 11 citedOpen Access
Aminoquinazolines as TRPV1 antagonists: Modulation of drug-like properties through the exploration of 2-position substitution
Bioorganic & Medicinal Chemistry Letters·2008· 18 citedOpen Access
Hunting for ion channel modulators with herpes simplex virus
Nature Methods·2007· 1 cited
Increased TRPA1, TRPM8, and TRPV2 expression in dorsal root ganglia by nerve injury
Biochemical and Biophysical Research Communications·2007· 140 cited
Erratum: The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept
Nature Reviews Drug Discovery·2007· 3 citedOpen Access
The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept
Nature Reviews Drug Discovery·2007· 873 cited
TRP channels and pain
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease·2007· 112 citedOpen Access
Leukocyte Effects of C5a-Receptor Blockade During Simulated Extracorporeal Circulation
The Annals of Thoracic Surgery·2006· 19 cited
Inflammation-Induced Reduction of Spontaneous Activity by Adjuvant: A Novel Model to Study the Effect of Analgesics in Rats
Journal of Pharmacology and Experimental Therapeutics·2006· 97 cited
From arylureas to biarylamides to aminoquinazolines: Discovery of a novel, potent TRPV1 antagonist
Bioorganic & Medicinal Chemistry Letters·2006· 30 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

James E. Krause(18), A Szállaśi(9), Charles A. Blum(6), Daniel C. Broom(6), David J. Matson(6), Bertrand L. Chenard(6), Marci Crandall(5), Kevin J. Hodgetts(5), Peter M. Blumberg(4), Audrey F. Seasholtz(4), Xiaozhang Zheng(4), Rajagopal Bakthavatchalam(4), Samer R. Eid(3), Marianne E. Buck(3), Robin Meade(3), Harry L. Brielmann(3), Stéphane De Lombaert(3), Mark T. Kershaw(3), A. Brian Jones(3), Alan Hutchison(3)